{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-067033","form_type":"8-K","ticker":"SLS","cik":"0001390478","company_name":"SELLAS Life Sciences Group, Inc.","filed_at":"2023-06-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.672733+00:00","generated_at":"2026-06-14T09:10:50.990853+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"SELLAS to begin Phase 2a AML trial of CDK9 inhibitor GFH009; Phase 1 showed complete response in monotherapy","bullets":["Phase 2a single-arm trial to enroll up to 20 R/R AML patients previously failed venetoclax/azacitidine; primary endpoints: composite CR rate, duration of response, safety.","Trial expected to open June 2023 with top-line data by end of 2023; GFH009 dosed at 45 or 60 mg weekly in combination with standard aza/ven.","Phase 1 produced the first known complete response (MRD-negative, >6 months) from a CDK9 inhibitor monotherapy in R/R AML; no DLTs observed.","GFH009 targets MCL1 transcription, synergizing with BCL2 inhibitor venetoclax; triple combo may overcome venetoclax resistance by hitting both anti-apoptotic pathways.","GPS Phase 3 REGAL AML IDMC meeting set for Q3 2023; interim analysis expected by year-end 2023 or early 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-067033","json":"https://secwatch.observer/filing/0001104659-23-067033.json","markdown":"https://secwatch.observer/filing/0001104659-23-067033.md","text":"https://secwatch.observer/filing/0001104659-23-067033.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1390478/000110465923067033/0001104659-23-067033-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1390478/000110465923067033/tm2317574d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T09:10:50.990853+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}